Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine-Reference-Cited by-同舟云学术

Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine

Published:2014-02 Issue:2 Volume:4 Page:e187-e187
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Miltiades P, ,Lamprianidou E,Vassilakopoulos T P,Papageorgiou S G,Galanopoulos A G,Vakalopoulou S,Garypidou V,Papaioannou M,Hadjiharissi E,Pappa V,Papadaki H A,Spanoudakis E,Tsatalas K,Kotsianidis I

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj20149.pdf

Reference15 articles.

1. Terwijn M, Feller N, van Rhenen A, Kelder A, Westra G, Zweegman S et al. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur J Cancer 2009; 45: 1692–1699.

2. Gonen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012; 120: 2297–2306.

3. Cerny J, Yu H, Ramanathan M, Raffel GD, Walsh WV, Fortier N et al. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br J Haematol 2013; 160: 262–266.

4. Nakase K, Kita K, Miwa H, Nishii K, Shikami M, Tanaka I et al. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia 2007; 21: 326–332.

5. Paietta E, Racevskis J, Neuberg D, Rowe JM, Goldstone AH, Wiernik PH . Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia 1997; 11: 1887–1890.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients;Biomedicine & Pharmacotherapy;2023-09

2. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine;Epigenomics;2021-07

3. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients;Cancer Biomarkers;2020-09-25

4. IL2RA Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia;Cancer Research;2020-09-01

5. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study;Leukemia Research;2020-08